# Maintenance Therapy for Small-cell Lung Cancer

> **NCT03769935** · PHASE2 · COMPLETED · sponsor: **Qingdao Central Hospital** · enrollment: 90 (actual)

## Conditions studied

- Progression Free Survival

## Interventions

- **DRUG:** cis Platinum, etoposide, S1

## Key facts

- **NCT ID:** NCT03769935
- **Lead sponsor:** Qingdao Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03769935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03769935, "Maintenance Therapy for Small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03769935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*